Regulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on RGLS. Leerink Partnrs reiterated an “outperform” rating on shares of Regulus Therapeutics in a report on Monday, March 18th. Canaccord Genuity Group cut their price target on Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, March 19th. Wells Fargo & Company increased their price target on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Regulus Therapeutics in a report on Monday, March 25th. Finally, SVB Leerink assumed coverage on Regulus Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating and a $6.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock opened at $2.54 on Monday. Regulus Therapeutics has a one year low of $0.85 and a one year high of $3.79. The stock’s 50-day moving average is $1.89 and its 200 day moving average is $1.52. The firm has a market cap of $166.27 million, a price-to-earnings ratio of -1.60 and a beta of 1.57.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). On average, sell-side analysts expect that Regulus Therapeutics will post -0.52 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Federated Hermes Inc. bought a new stake in Regulus Therapeutics during the first quarter worth $8,656,000. FMR LLC raised its stake in shares of Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after purchasing an additional 716,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Regulus Therapeutics by 21.4% in the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 648,121 shares during the last quarter. Exome Asset Management LLC purchased a new position in shares of Regulus Therapeutics in the 4th quarter worth about $228,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Regulus Therapeutics by 498.2% in the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 111,100 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.